NulibryActive Ingredient(s): Fosdenopterin
FDA Approved: * February 26, 2021
Pharm Company: * ORIGIN BIOSCIENCES INC
Category: Genetic Disorders
Fosdenopterin (or cyclic pyranopterin monophosphate, cPMP), sold under the brand name Nulibry, is a medication used to reduce the risk of death due to a rare genetic disease known as molybdenum cofactor deficiency type A. The most common side effects include complications related to the intravenous line, fever, respiratory infections, vomiting, gastroenteritis, and diarrhea. Fosdenopterin was approved for medical use in the United States in February 2021.... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Nulibry 9.5 mg Intravenous Injection, Powder, Lyophilized, for SolutionNDC: 73129-001
Origin Biosciences, Inc.